2-(4-Bromo-2,6-dimethylphenoxy)acetic acid, 98%, 1g

(R)-(+)-N,N-DIMETHYL-1-PHENYLETHYLAMINE, 95%, 100g

1H-Indazole-4-carboxylic acid, 95.0%, 250mg

4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine, 95.0%, 5g

(6-(Piperidin-1-yl)-5-(trifluoromethyl)pyridin-3-yl)boronic acid, 97%, 250mg

(2-Methyl-4-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid, 95.0%, 1g

1-(2-methoxybenzoyl)-1,4-diazepane, 95.0%, 1g

4-Chloro-3',4'-dimethoxybenzophenone, 97.0%, 5g

2H-Pyran-2,4,6(3H,5H)-trione, 95.0%, 1g

1-[5-(tetrahydro-2-furanyl)-1,2,4-oxadiazol-3-yl]methanamine, 95.0%, 250mg

2-[(Prop-2-ynyloxy)methyl]oxirane, 95.0%, 1g

Objectif à contraste de phase Plan PLPH S100x/1,25

6-quinolinemethanol, 95.0%, 250mg